ContraVir Pharmaceuticals Inc (CTRV) stock jumped almost 28% after the company presented positive interim data for CMX157, an equivalent to tenofovir, to treat hepatitis B.
The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to Gilead’s (GILD) tenofovir disoproxil fumarate, known as Viread.
“We are pleased and excited with these clinical results, as they demonstrate CMX157’s great potential in our ongoing effort to develop a cure for HBV,” said CEO James Sapirstein. “The significant viral load reduction and favorable safety at this low dose of CMX157 speaks to the unique liver-targeting mechanism of our drug, which concentrates the antiviral activity of tenofovir in the liver, enabling anti-HBV efficacy at lower doses and minimal drug exposure to other tissues. We believe, based on the data that are being generated, that CMX157 has great potential as a safe and highly potent backbone of combination therapy against HBV.”